RESP

Marginal versus conditional odds ratios when updating risk prediction models

Epidemiology. 2022 Jul 1;33(4):555-558. doi: 10.1097/EDE.0000000000001489.

                        Model-Based ROC Curve: Examining the Effect of Case Mix and Model Calibration on the ROC Plot
                      

Medical Decision Making. October 2021. doi:10.1177/0272989X211050909

Uncertainty and the value of information in risk prediction modeling

Sadatsafavi M, Yoon Lee T, Gustafson P. Uncertainty and the Value of Information in Risk Prediction Modeling. Med Decis Making. 2022 Jul;42(5):661-671. doi: 10.1177/0272989X221078789.

Sadatsafavi M, Yoon Lee T, Gustafson P. Uncertainty and the Value of Information in Risk Prediction Modeling. Med Decis Making....

Value-of-Information Analysis for External Validation of Risk Prediction Models

Med Decis Making. 2023 Jul;43(5):564-575. doi: 10.1177/0272989X231178317.

                        Methodological concerns about "concordance-statistic for benefit" as a measure of discrimination in predicting treatment benefit 
                      

Diagn Progn Res. 2023 May 16;7(1):10. doi: 10.1186/s41512-023-00147-z

Non-parametric inference on calibration of predicted risks

Stat Med. 2024 Jun 11. doi: 10.1002/sim.10138.

                        International variation in severe exacerbation rates in patients with severe asthma 
                      

Lee TY, Price D, Yadav CP, Roy R, Mien LLH, Wang E, Wechsler ME, Jackson DJ, Busby J, Heaney LG, Pfeffer PE, Mahboub B, Perng Steve DW, Cosio BG, Perez-de-Llano L, Al-Lehebi R, Larenas-Linnemann D, Al-Ahmad M, Rhee CK, Iwanaga T, Heffler E, Canonica GW, Co...

Lee TY, Price D, Yadav CP, Roy R, Mien LLH, Wang E, Wechsler ME, Jackson DJ, Busby J, Heaney LG, Pfeffer PE, Mahboub B, Perng St...

QRISK3 underestimates the risk of cardiovascular events in patients with COPD

Amegadzie JE, Gao Z, Quint JK, Russell R, Hurst JR, Lee TY, Sin DD, Chen W, Bafadhel M, Sadatsafavi M. QRISK3 underestimates the risk of cardiovascular events in patients with COPD. Thorax. 2023 Nov 27:thorax-2023-220615. doi: 10.1136/thorax-2023-220615. E...

Amegadzie JE, Gao Z, Quint JK, Russell R, Hurst JR, Lee TY, Sin DD, Chen W, Bafadhel M, Sadatsafavi M. QRISK3 underestimates the...

                        A Cost-Effectiveness Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
                      

Ahmadian S, Johnson KM, Ho JK, Sin DD, Lynd LD, Harrison M, Sadatsafavi M. A Cost-Effectiveness Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2023 Dec;20(12):1735-1742. doi:...

Ahmadian S, Johnson KM, Ho JK, Sin DD, Lynd LD, Harrison M, Sadatsafavi M. A Cost-Effectiveness Analysis of Azithromycin for the...

                        High-Efficiency Particulate Air Filters for Preventing Wildfire-related Asthma Complications: A Cost-Effectiveness Study
                      

Adibi A, Barn P, Shellington EM, Harvard S, Johnson KM, Carlsten C. High-Efficiency Particulate Air Filters for Preventing Wildfire-related Asthma Complications: A Cost-Effectiveness Study. Am J Respir Crit Care Med. 2024 Jan 15;209(2):175-184. doi: 10.116...

Adibi A, Barn P, Shellington EM, Harvard S, Johnson KM, Carlsten C. High-Efficiency Particulate Air Filters for Preventing Wildf...

                        Cost-effectiveness of budesonide-formoterol vs inhaled epinephrine in US adults with mild asthma
                      

Ho JK, Shaker M, Greenhawt M, Sadatsafavi M, Abrams EM, Oppenheimer J, Mosnaim GS, Lee TY, Johnson KM. Cost-effectiveness of budesonide-formoterol vs inhaled epinephrine in US adults with mild asthma. Ann Allergy Asthma Immunol. 2023 Oct 23:S1081-1206(23)0...

Ho JK, Shaker M, Greenhawt M, Sadatsafavi M, Abrams EM, Oppenheimer J, Mosnaim GS, Lee TY, Johnson KM. Cost-effectiveness of bud...

                        A long overdue recognition: COPD as a distinct predictor of cardiovascular disease risk.
                      

Amegadzie JE, Sadatsafavi M. A long overdue recognition: COPD as a distinct predictor of cardiovascular disease risk. Eur Respir J. 2023 Aug 31;62(2):2301167. doi: 10.1183/13993003.01167-2023

Amegadzie JE, Sadatsafavi M. A long overdue recognition: COPD as a distinct predictor of cardiovascular disease risk. Eur Respir...

                        Trends in hospital admissions for chronic obstructive pulmonary disease over 16 years in Canada
                      

Amegadzie JE, Lee TY, Sadatsafavi M, Lynd LD, Sin DD, Johnson KM. Trends in hospital admissions for chronic obstructive pulmonary disease over 16 years in Canada. CMAJ. 2023 Sep 11;195(35):E1172-E1179. doi: 10.1503/cmaj.221051.

Amegadzie JE, Lee TY, Sadatsafavi M, Lynd LD, Sin DD, Johnson KM. Trends in hospital admissions for chronic obstructive pulmonar...

                        Risk and distribution of chronic obstructive pulmonary disease-related hospitalizations among primary care patients
                      

Can Fam Physician. 2023 Jun;69(6):409-414. doi: 10.46747/cfp.6906409. PMID: 37315968; PMCID: PMC10266388.

Generalizability of Risk Stratification Algorithms for Exacerbations in COPD

IMPACT Study. Generalizability of Risk Stratification Algorithms for Exacerbations in COPD. Chest. 2023 Apr;163(4):790-798. doi: 10.1016/j.chest.2022.11.041

IMPACT Study. Generalizability of Risk Stratification Algorithms for Exacerbations in COPD. Chest. 2023 Apr;163(4):790-798. doi:...

                        Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials
                      

Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials. Respir Res. 2023 May 2;24(1):120. doi: 10.1186/s12931-023-02409-2.

Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials. Respir Res. 202...

                        A parametric model to jointly characterize rate, duration, and severity of exacerbations in episodic diseases
                      

A parametric model to jointly characterize rate, duration, and severity of exacerbations in episodic diseases. BMC Med Inform Decis Mak. 2023 Jan 12;23(1):6. doi: 10.1186/s12911-022-02080-5

A parametric model to jointly characterize rate, duration, and severity of exacerbations in episodic diseases. BMC Med Inform De...

                        IMplementing Predictive Analytics towards efficient COPD Treatments (IMPACT): protocol for a stepped-wedge cluster randomized impact study
                      

IMPACT Study Group. IMplementing Predictive Analytics towards efficient COPD Treatments (IMPACT): protocol for a stepped-wedge cluster randomized impact study. Diagn Progn Res. 2023 Feb 14;7(1):3. doi: 10.1186/s41512-023-00140-6

IMPACT Study Group. IMplementing Predictive Analytics towards efficient COPD Treatments (IMPACT): protocol for a stepped-wedge c...

                        Individualised risk prediction model for exacerbations in patients with severe asthma: protocol for a multicentre real-world risk modelling study
                      

Individualised risk prediction model for exacerbations in patients with severe asthma: protocol for a multicentre real-world risk modelling study. BMJ Open. 2023 Mar 9;13(3):e070459. doi: 10.1136/bmjopen-2022-070459

Individualised risk prediction model for exacerbations in patients with severe asthma: protocol for a multicentre real-world ris...

                        IMplementing Predictive Analytics towards efficient COPD Treatments (IMPACT): protocol for a stepped-wedge cluster randomized impact study. 
                      

Michaux KD, Metcalfe RK, Burns P, Conklin AI, Hoens AM, Smith D, Struik L, Safari A, Sin DD, Sadatsafavi M; IMPACT Study Group. IMplementing Predictive Analytics towards efficient COPD Treatments (IMPACT): protocol for a stepped-wedge cluster randomized im...

Michaux KD, Metcalfe RK, Burns P, Conklin AI, Hoens AM, Smith D, Struik L, Safari A, Sin DD, Sadatsafavi M; IMPACT Study Group....

                        Health economists on involving patients in modeling: potential benefits, harms, and variables of interest
                      

Harvard S, Werker GR. Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest. Pharmacoeconomics. 2021 Jul;39(7):823-833. doi: 10.1007/s40273-021-01018-5.

Harvard S, Werker GR. Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest...

                        Value judgments in a COVID-19 vaccination model: a case study in the need for public involvement in health-oriented modelling.
                      

Harvard S, Winsberg E, Symons J, Adibi A. Value judgments in a COVID-19 vaccination model: A case study in the need for public involvement in health-oriented modelling. Soc Sci Med. 2021 Oct;286:114323. doi: 10.1016/j.socscimed.2021.114323.

Harvard S, Winsberg E, Symons J, Adibi A. Value judgments in a COVID-19 vaccination model: A case study in the need for public i...

Causal inference, moral intuition, and modeling in a pandemic

Harvard, S., & Winsberg, E. (2021). Causal Inference, Moral Intuition, and Modeling in a Pandemic. Philosophy of Medicine, 2(2). https://doi.org/10.5195/pom.2021.70

Harvard, S., & Winsberg, E. (2021). Causal Inference, Moral Intuition, and Modeling in a Pandemic. Philosophy of Medicine, 2(2)....

Epistemic risk in representation

Harvard S, Winsberg E. The Epistemic Risk in Representation. Kennedy Inst Ethics J. 2022;32(1):1-31. doi: 10.1353/ken.2022.0001. PMID: 35431275.

Harvard S, Winsberg E. The Epistemic Risk in Representation. Kennedy Inst Ethics J. 2022;32(1):1-31. doi: 10.1353/ken.2022.0001....

Purposes and duties in scientific modelling

Winsberg E, Harvard S. Purposes and duties in scientific modelling. J Epidemiol Community Health. 2022 Jan 13:jech-2021-217666. doi: 10.1136/jech-2021-217666.

Winsberg E, Harvard S. Purposes and duties in scientific modelling. J Epidemiol Community Health. 2022 Jan 13:jech-2021-217666....

                        Development of a conceptual model of childhood asthma to inform asthma prevention policies
                      

Adibi A, Turvey SE, Lee TY, Sears MR, Becker AB, Mandhane PJ, Moraes TJ, Subbarao P, Sadatsafavi M. Development of a conceptual model of childhood asthma to inform asthma prevention policies. BMJ Open Respir Res. 2021 Nov;8(1):e000881. doi: 10.1136/bmjresp...

Adibi A, Turvey SE, Lee TY, Sears MR, Becker AB, Mandhane PJ, Moraes TJ, Subbarao P, Sadatsafavi M. Development of a conceptual...

                        Long-term natural history of severe asthma exacerbations and their impact on the disease course
                      

Lee TY, Petkau J, Sadatsafavi M. Long-Term Natural History of Severe Asthma Exacerbations and Their Impact on the Disease Course. Ann Am Thorac Soc. 2022 Jun;19(6):907-915. doi: 10.1513/AnnalsATS.202012-1562OC.

Lee TY, Petkau J, Sadatsafavi M. Long-Term Natural History of Severe Asthma Exacerbations and Their Impact on the Disease Course...

                        Validation of the 4C prediction models to inform care for patients with COVID-19: final steps towards clinical application
                      

Puhan MA, Sadatsafavi M. Validation of the 4C prediction models to inform care for patients with COVID-19: final steps towards clinical application. Thorax. 2022 Jun;77(6):536. doi: 10.1136/thoraxjnl-2021-218313.

Puhan MA, Sadatsafavi M. Validation of the 4C prediction models to inform care for patients with COVID-19: final steps towards c...

                        The hidden and unchecked judgement calls when using exacerbation history for managing COPD
                      

Sadatsafavi M, Aaron SD, Gershon AS, Puhan M, Adibi A, Sin DD. The Hidden and Unchecked Judgement Calls When Using Exacerbation History for Managing COPD. Arch Bronconeumol. 2022 Sep;58(9):629-631. English, Spanish. doi: 10.1016/j.arbres.2021.09.018.

Sadatsafavi M, Aaron SD, Gershon AS, Puhan M, Adibi A, Sin DD. The Hidden and Unchecked Judgement Calls When Using Exacerbation...

                        Benefit-harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease
                      

Ahmadian S, Sin DD, Lynd L, Harrison M, Sadatsafavi M. Benefit-harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2022 Nov;77(11):1079-1087. doi: 10.1136/thoraxjnl-2021-217962.

Ahmadian S, Sin DD, Lynd L, Harrison M, Sadatsafavi M. Benefit-harm analysis of azithromycin for the prevention of acute exacerb...

                        A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study
                      

Gupta S, Panchal P, Sadatsafavi M, Ghanouni P, Sin D, Pakhale S, To T, Zafari Z, Nimmon L; Canadian Respiratory Research Network. A personalized biomedical risk assessment infographic for people who smoke with COPD: a qualitative study. Addict Sci Clin Pra...

Gupta S, Panchal P, Sadatsafavi M, Ghanouni P, Sin D, Pakhale S, To T, Zafari Z, Nimmon L; Canadian Respiratory Research Network...

                        Association between asthma control trajectories in preschoolers and long-term asthma control
                      

Longo C, Blais L, Brownell M, Quail JM, Sadatsafavi M, Forget A, Turcot MA, Li W, Sidhu N, Tavakoli H, Tan Q, Platt RW, Ducharme FM. Association Between Asthma Control Trajectories in Preschoolers and Long-Term Asthma Control. J Allergy Clin Immunol Pract....

Longo C, Blais L, Brownell M, Quail JM, Sadatsafavi M, Forget A, Turcot MA, Li W, Sidhu N, Tavakoli H, Tan Q, Platt RW, Ducharme...

External validation of lung function predictions in real-world cohorts of COPD

Zafari Z, Lee TY, Sadatsafavi M. External validation of lung function predictions in real-world cohorts of COPD. Respir Med. 2022 Jul;198:106859. doi: 10.1016/j.rmed.2022.106859.

Zafari Z, Lee TY, Sadatsafavi M. External validation of lung function predictions in real-world cohorts of COPD. Respir Med. 202...

16-year trends in asthma hospital admissions in Canada

Lee TY, Petkau J, Mangat N, Safari A, Cragg JJ, Lynd LD, FitzGerald JM, Turvey SE, Sadatsafavi M. 16-year trends in asthma hospital admissions in Canada. Ann Allergy Asthma Immunol. 2022 Oct;129(4):475-480.e2. doi: 10.1016/j.anai.2022.06.022.

Lee TY, Petkau J, Mangat N, Safari A, Cragg JJ, Lynd LD, FitzGerald JM, Turvey SE, Sadatsafavi M. 16-year trends in asthma hospi...

                        The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study
                      

Golam SM, Janson C, Beasley R, FitzGerald JM, Harrison T, Chipps B, Hughes R, Müllerová H, Olaguibel JM, Rapsomaniki E, Reddel HK, Sadatsafavi M; NOVELTY study investigators. The burden of mild asthma: Clinical burden and healthcare resource utilisation in...

Golam SM, Janson C, Beasley R, FitzGerald JM, Harrison T, Chipps B, Hughes R, Müllerová H, Olaguibel JM, Rapsomaniki E, Reddel H...

                        ACCEPT 2·0: Recalibrating and externally validating the Acute COPD exacerbation prediction tool (ACCEPT)
                      

Safari A, Adibi A, Sin DD, Lee TY, Ho JK, Sadatsafavi M. ACCEPT 2·0: Recalibrating and externally validating the Acute COPD exacerbation prediction tool (ACCEPT). EClinicalMedicine. 2022 Jul 22;51:101574. doi: 10.1016/j.eclinm.2022.101574.

Safari A, Adibi A, Sin DD, Lee TY, Ho JK, Sadatsafavi M. ACCEPT 2·0: Recalibrating and externally validating the Acute COPD exac...

                        Developing an online infrastructure to enhance model accessibility and validation: The Peer Models Network
                      

Harvard S, Adibi A, Easterbrook A, Werker GR, Murphy D, Grant D, Mclean A, Majdzadeh Z, Sadatsafavi M. Developing an online infrastructure to enhance model accessibility and validation: The Peer Models Network. Pharmacoeconomics. 2022 Oct;40(10):1005-1009....

Harvard S, Adibi A, Easterbrook A, Werker GR, Murphy D, Grant D, Mclean A, Majdzadeh Z, Sadatsafavi M. Developing an online infr...

Generalizability of risk stratification algorithms for exacerbations in COPD

Ho JK, Safari A, Adibi A, Sin DD, Johnson K, Sadatsafavi M; IMPACT study. Generalizability of risk stratification algorithms for exacerbations in COPD. Chest. 2022 Dec 9:S0012-3692(22)04216-7. doi: 10.1016/j.chest.2022.11.041.

Ho JK, Safari A, Adibi A, Sin DD, Johnson K, Sadatsafavi M; IMPACT study. Generalizability of risk stratification algorithms for...

                        The economics of precision health: preventing air pollution-induced exacerbation in asthma
                      

The demonstrable value of precision medicine, in the context of common environmental exposures, has scarcely been explored. This study evaluated the cost effectiveness of a preventive personalised intervention to reduce the adverse effect of air pollution...

The demonstrable value of precision medicine, in the context of common environmental exposures, has scarcely been explored. This...

                        Trends in oral corticosteroids use in severe asthma: a 14-year population-based study
                      

Respir Res. 2021 Apr 9;22(1):103. doi: 10.1186/s12931-021-01696-x

                        Moving beyond AUC: decision curve analysis for quantifying net benefit of risk prediction models
                      

Eur Respir J. 2021 Sep 9:2101186. doi: 10.1183/13993003.01186-2021

                        The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada 
                      

Allergy Asthma Clin Immunol. 2021 Oct 12;17(1):108. doi: 10.1186/s13223-021-00610-w. PMID: 34641954.

                        Development and validation of the Evaluation Platform In COPD (EPIC): a population-based outcomes model of COPD for Canada
                      

Med Decis Making. 2019 Feb;39(2):152-16

                        Validation and Utility Testing of Clinical Prediction Models: Time to Change the Approach
                      

JAMA. 2020 Jul 21;324(3):235-236

Testing Clinical Prediction Models—Reply

We agree with Drs Goldstein and Pencina about the necessity of adapting risk models to the clinical use case. We share their vision that a cloud-based platform does not have to be centralized; each practitioner will set up their own environment for the mod...

We agree with Drs Goldstein and Pencina about the necessity of adapting risk models to the clinical use case. We share their vis...

International severe asthma registry (ISAR): protocol for a global registry

The International Severe Asthma Registry (ISAR) is a collaborative initiative comprising existing and new registries that builds on data from multiple nations and regions and increases the statistical power and comparability of data. It is the first global...

The International Severe Asthma Registry (ISAR) is a collaborative initiative comprising existing and new registries that builds...

                        Understanding resource utilization and mortality in COPD to support policy making: A microsimulation study
                      

The aim of this study is to develop a platform that allows: 1) policymakers to identify subgroups of the COPD population that are at increased risk of emergency department visits, hospitalization and mortality and 2) health economists to obtain input or va...

The aim of this study is to develop a platform that allows: 1) policymakers to identify subgroups of the COPD population that ar...

                        The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline
                      

There is sparse evidence that COPD exacerbations are associated with subsequent accelerated lung function decline, particularly in those with mild disease. Lung function decline is most accelerated at the early stages of COPD, and early identification of p...

There is sparse evidence that COPD exacerbations are associated with subsequent accelerated lung function decline, particularly...

                        Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?
                      

Eur Respir J. 2020 Aug 27;2002122. doi: 10.1183/13993003.02122-2020.

                        Predicting Severe COPD Exacerbations: Developing a Population Surveillance Approach with Administrative Data
                      

Ann Am Thorac Soc. 2020 May 8.

                        Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study
                      

Respir Res. 2020 May 19;21(1):118

                        The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK
                      

Respiratory Medicine, 2020 (171); 106079

                        Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline
                      

The purpose of this clinical practice guideline is to address specific clinically important questions regarding the pharmacologic management of COPD. The expert panel, in collaboration with a team of methodologists, prioritized and developed six questions...

The purpose of this clinical practice guideline is to address specific clinically important questions regarding the pharmacologi...

The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study

This Lancet Respiratory Medicine describes a new prediction model to predict COPD exacerbations using simple clinical predictors

                        A Threshold-Free Summary Index for Quantifying the Capacity of Covariates to Yield Efficient Treatment Rules
                      

Statistic in Medicine. 2020;10.1002/sim.8481

Looking at the COPD spectrum through “PRISm”

A comment on the study "Preserved ratio impaired spirometry (PRISm) is a prevalent, neglected condition whose prognosis is close to that of COPD" by Wijnant et al. Given that PRISm resembles COPD in term of reduction in FEV1, but not in terms of FEV1/FVC r...

A comment on the study "Preserved ratio impaired spirometry (PRISm) is a prevalent, neglected condition whose prognosis is close...

                        Cost-effectiveness of Implementing Objective Diagnostic Verification of Asthma in the United States 
                      

J Allergy Clin Immunol. 2019;S0091-6749(19)31634-3

                        The association between rate and severity of exacerbations in chronic obstructive pulmonary disease: an application of a joint frailty-logistic model
                      

Am J Epidemiol. 2016;184(9):681–689

                        Individualized prediction of lung-function decline in chronic obstructive pulmonary disease
                      

CMAJ. 2016;188(14):1004–1011

                        The Impact of Care Specialty on Survival-Adjusted Medical Costs of COPD Patients After a Hospitalization: a longitudinal analysis.
                      

J Gen Intern Med. 2018 Sep;33(9):1528-1535

                        Stability of asthma symptom control in a longitudinal study of mild–moderate asthmatics
                      

J Allergy Clin Immunol Pract. 2017 Nov - Dec;5(6):1663-1670.e5

                        Complementary and alternative asthma treatments and their association with asthma control: a population-based study
                      

BMJ Open. 2013 Sep 4;3(9):e003360

                        History of Asthma in Patients with Chronic Obstructive Pulmonary Disease: A Comparative Study of Economic Burden.
                      

Ann Am Thorac Soc. 2016 Feb;13(2):188-96

                        The preventable burden of productivity loss due to suboptimal asthma control: a population-based study
                      

Chest. 2014 Apr;145(4):787-793

The impact of comorbidities on productivity loss in asthma patients

Respir Res. 2016 Aug 26;17(1):106

                        Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study
                      

Arch Osteoporos. 2018 Oct 29;13(1):116

                        A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma
                      

J Asthma. 2019 Dec;56(12):1334-1346

                        Asthma is not associated with the need for surgery in Crohn’s disease when controlling for smoking status: a population-based cohort study. 
                      

Clin Epidemiol. 2018 Jul 12;10:831-840

The diagnostic performance of patient symptoms in screening for COPD

Respir Res. 2018 Feb 7;19(1):26

                        Characterizing undiagnosed chronic obstructive pulmonary disease: a systematic review and meta-analysis
                      

Respir Res. 2018 Feb 7;19(1):26

                        Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
                      

Cost Eff Resour Alloc. 2018 Jan 30;16:3

The importance of measuring asthma control in emerging economies.

Int J Tuberc Lung Dis. 2014 Mar;18(3):254

                        The projected economic and health burden of sub-optimal asthma control in Canada
                      

Respir Med. 2018 May;138:7-12

                        Relative Impact Characteristic (RIC) curve: a graphical tool to visualize and quantify the clinical utility and population-level consequences of implementing markers
                      

Ann Epidemiol. 2018 Oct;28(10):717-723.e3

                        Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcome
                      

Pharmacoeconomics. 2014 Oct;32(10):995-1004

COPD: undefeated!

Chest. 2015 Apr;147(4):868-869

The global economic burden of asthma and chronic obstructive pulmonary disease

Int J Tuberc Lung Dis. 2016 Jan;20(1):11-23

                        Future impact of various interventions on the burden of COPD in Canada: a dynamic population model.
                      

PLoS One. 2012;7(10):e46746

                        Has asthma medication use caught up with the evidence? A 12-year population-based study of trends
                      

Chest. 2017 Mar;151(3):612-618

                        Predictors of inappropriate usage of reliever medications in asthma: a 12-year population-based study
                      

BMC Pulm Med. 2018 Feb 12;18(1):33.

                        Dispensation of long-acting β agonists with or without inhaled corticosteroids, and risk of asthma-related hospitalisation: a population-based study
                      

Thorax. 2014 Apr;69(4):328-34

                        Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: a population-based study
                      

J Allergy Clin Immunol. 2013 Jul;132(1):63-9

                        A statistical method was used for the meta-analysis of tests for latent TB in the absence of a gold standard, combining random-effect and latent-class methods to estimate test accuracy
                      

J Clin Epidemiol. 2010 Mar;63(3):257-69

                        Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
                      

Lancet Respir Med. 2015 Aug;3(8):631-9

                        Influences of Socioeconomic Status on Costs of Asthma Under Universal Health Coverage
                      

Med Care. 2016 Aug;54(8):789-95

Excess medical costs in patients with asthma and the role of comorbidity

Eur Respir J. 2016 Dec;48(6):1584-1592

Ten-year trends in direct costs of asthma: a population-based study

Allergy. 2017 Feb;72(2):291-299

                        Economic and health effect of full adherence to controller therapy in adults with uncontrolled asthma: A simulation study
                      

J Allergy Clin Immunol. 2014 Oct;134(4):908-915.e3

                        The Projected Epidemic Of COPD Hospitalizations Over the Next 15 Years: A Population Based Perspective
                      

Am J Respir Crit Care Med. 2017 Feb 1;195(3):287-291

                        The natural history of severe asthma and influences of early risk factors: a population-based cohort study
                      

Thorax. 2016 Mar;71(3):267-75

                        Cost-effectiveness of bronchial thermoplasty, omalizumab, and standard therapy for moderate-to-severe allergic asthma
                      

PLoS One. 2016 Jan 11;11(1):e0146003

                        Incorporating external evidence in trial-based cost-effectiveness analysis: the use of resampling methods
                      

Trials. 2014 Jun 3;15:201

                        The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis – a case study of pharmacotherapies for moderate to severe COPD
                      

Cost Eff Resour Alloc. 2014 Mar 13;12(1):8

                        Two-level resampling as a novel method for calculation of the expected value of sample information in economic trials
                      

Health Econ. 2013 Jul;22(7):877-82

                        A Quantitative Benefit-Risk Analysis of Isoniazid for Treatment of Latent Tuberculosis Infection Using Incremental Benefit Framework
                      

Value Health. 2013 Jan-Feb;16(1):66-75

                        Excess economic burden of comorbidities in COPD: a 15-year population-based study
                      

Eur Respir J. 2017 Jul 27;50(1). pii: 1700393

Faculty of Pharmaceutical Sciences & UBC Division of Respiratory Medicine Respiratory Evaluation Sciences Program

Faculty of Pharmaceutical Sciences & UBC Division of Respiratory Medicine
Respiratory Evaluation Sciences Program